BridgeMD
A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
EU CTIS ID: 2024-512146-41-00
What this study is testing
- To characterize the safety, toxicity, and tolerability of etentamig when co-administered with iberdomide in subjects with Relapsed/Refractory Multiple Myeloma (RRMM) - To determine the recommended doses of etentamig and iberdomide combination treatment in subjects with RRMM.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Eastern Cooperative Oncology Group (ECOG) performance of 0 to 1.
- Must have confirmed diagnosis of Relapsed/Refractory Multiple Myeloma (RRMM) after the participant's last treatment, as outlined in the protocol.
- All participants must have measurable diseases per central laboratory as outlined in protocol
You likely can't join if
- Has received prior etentamig treatment
- Has received prior cereblon E3 ligase modulatory drug (CELMoD) (iberdomide or mezigdomide).
- Has received a peripheral ASCT within 12 weeks, or an allogeneic SCT within ≤ 6 months of the first dose of study treatment. Subjects with allogenic stem cell transplant should not have any symptoms of acute or chronic graft versus host disease.
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- Canada
- Australia
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; Canada; Australia; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.